Ipsen’s 2010 results and 2011 sales objectives
2.3.2011 07:00:38 CET | Business Wire | Press release
- Constant currency drug sales 1 growth of 5.1% and of 11.0% for Specialty Care
- Non-recurring and non cash impairments and depreciations of €80.3 million after tax
- Non-recurring after tax profit of €41.2 million relating to the return of taspoglutide’s rights
- Reported operating profit of €128.8 million, down 25.3% - Recurring adjusted 2 operating profit of €183.2 million, up 26.8%
- Fully diluted EPS of €1.13, down 39.2% - Recurring adjusted 2 diluted EPS of €1.64, up 2.5%
- Net cash flow of €253.9 million generated by operating activities in 2010
- Proposed dividend of €0.80 per share, up 6.7%
Regulatory News:
The Board of Directors of Ipsen (Paris:IPN) (Euronext : IPN ; ADR : IPSEY), chaired by Marc de Garidel, met on 1 March 2011 to review the Group’s results for 2010, published today. The annual financial report, with regards to the regulated information, will be available on the Group’s website, www.ipsen.com , Investor Relations section.
|
Extract from audited consolidated results for 2009 and 2010 (in million euros) |
||||||
| 2010 | 2009 | % change | ||||
| Drug sales | 1 068.3 | 1 002.6 | +6.5% | |||
| Sales | 1 100.2 | 1 032.8 | +6.5% | |||
| Total revenues | 1 170.3 | 1 112.4 | +5.2% | |||
| Operating profit | 128.8 | 172.5 | (25.3%) | |||
|
Operating margin 3 |
11.7% | 16.7% | - | |||
| Recurring adjusted 2 operating profit | 183.2 | 144.4 | +26.8% | |||
| Recurring adjusted 2 operating margin 3 | 16.6% | 14.0% | - | |||
|
Consolidated profit 4 |
95.3 | 156.6 | (39.1%) | |||
| Earnings per share – fully diluted (€) | 1.13 | 1.86 | (39.2%) | |||
| Recurring adjusted 2 EPS – fully diluted (€) | 1.64 | 1.60 | +2.5% | |||
| Weighted average number of shares: | ||||||
| Outstanding | 84 379 443 | 84 303 607 | +0.1% | |||
| Fully diluted | 84 379 443 | 84 329 880 | +0.1% | |||
1 2009 sales figures have been restated with 2010 average exchange rate.
2 « Recurring adjusted »: Reconciliations between results and recurring adjusted results for 2010 and 2009 are detailed in appendix 4.
3 In percentage of sales
4 Attributable to Ipsen SA shareholders
Commenting on the 2010 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen , said: « Results for the year 2010 highlight Ipsen’s strategy: strong growth of Specialty Care products, a historical presence in the very dynamic emerging countries, an important contribution from partnerships to the Group’s growth and profitability, as well as sustained investment in Research and Development. These results also underline the challenges that the Group is confronted to: further price pressure, notably in Primary Care, attrition of some of our R&D projects, break-even still to be reached in North America. Furthermore, several one-off events weighted on Ipsen’s profitability in 2010. Nevertheless, on a recurring and adjusted basis, all 2010 financial objectives have been met.»
|
Comparison between the Group’s 2010 performance and its financial objectives |
||||
| Financial objectives | 2010 actuals | |||
|
Drug sales growth at constant currency5 |
3.0 to 5.0% | 5.1% | ||
| Other revenues |
Close to €50 million6 |
€55.1million6 | ||
| Recurring adjusted Operating Income |
15.0% growth7 |
+26.8% | ||
| Recurring adjusted Earnings per share |
Stable8 year-on-year |
€1.64
up 2.5% year on year |
||
Review of full year 2010 results
In 2010, Group drug sales grew 5.1% year-on-year – at constant currency – exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.
Consolidated Group sales reached €1,100.2 million for the full year 2010, up 5.0% year-on-year excluding foreign exchange impact.
Other revenues reached €70.1 million in 2010, down 11.9% year-on-year. In 2009, the Group recorded a non-recurring amount of €39.2 million relating to the favourable settlement of a dispute. In 2010, other revenues included industrial development expenses on OBI-1 of €15.0 million that the Group invoiced to Inspiration Biopharmaceuticals Inc.. Excluding these non-recurring items in both 2009 and 2010, other revenues increased by 36.3% year-on-year.
Total revenues amounted to €1,170.3 million, up 5.2% compared with 2009.
Cost of goods sold amounted to €236.2 million, or 21.5% of sales, compared to 23.0% a year ago. The strong improvement of the COGS to sale ratio reflected both the Group’s productivity efforts and the favourable mix associated with the growth in specialist care products.
Research and Development expenses reached €221.1 million in 2010, or 20.1% of sales, compared to 19.1% the previous year. Excluding the OBI-1 industrial development expenses which were entirely billed to Inspiration Biopharmaceuticals Inc., R&D expenses represented 18.8% of sales, up 1.8% year-on-year excluding foreign exchange impacts. In 2010, the main R&D projects included the clinical development of Somatuline® in neuroendocrine tumours (NET), the Post Marketing Approval studies requested by the FDA on Dysport® , the phase II clinical study for the sulfatase inhibitor, Irosustat® (BN-83495), and the analysis of the GuidAge® clinical trial results for Tanakan® . Furthermore, during this period, the Group recorded costs relating to the discontinuation of the BIM23A760 phase II clinical trial program in acromegaly.
5 2009 sales figures have been restated with 2010 average exchange rates
6 Excluding Group’s rebilled expenses for the industrial development of OBI-1 as anticipated in the agreements signed with Inspiration Biopharmaceuticals Inc.
7 Versus a recurring adjusted operating income of €144.4 million in 2009
8 Recurring adjusted earnings per share of €1.60 in 2009
Selling, general and administrative expenses represented €521.1 million in 2010, or 47.4% of sales, up 7.5% year-on-year. The Group rigorously implemented its marketing strategy, with the launches of its botulinum toxin type A in therapeutic use in the United States and aesthetic use both in the United States and in Europe, as well as the launch of the Decapeptyl® 6-month formulation in Europe and Adenuric® in France. The selling expenses increased by 4.5% year on year excluding foreign exchange impacts, reflecting the Group’s selective allocation policy to growth geographies such as China and Russia, in the context of declining French Primary care sales. Moreover, the Group wrote-down some receivables, mainly from public hospitals, particularly in Southern Europe (Greece, Spain, Portugal and Italy).
Reported operating income in 2010 amounted to €128.8 million, or 11.7% of sales, compared to €172.5 million, or 16.7% of sales, for the same period in 2009.
The 2010 reported operating income was notably affected by:
- A non recurring profit of €48.7 million relating to the accelerated recognition of the deferred revenues following the return of the rights for taspoglutide announced by Roche on 2 February 2011.
- A set of impairment charges, partially offset by a provision write-back, for a non-recurring net amount of €88.8 million. These impairments stemmed from: reduced forecast assumptions on the development and commercial prospects of IGF-1, depreciation of milestones relating to the agreement between the Group and GTx in oncology and to recent uncertainties in some neurology partnership development timelines.
Excluding purchase price allocation impacts and non-recurring elements relating to the return of taspoglutide’s rights and to the impairment charges, the Group’s recurring adjusted operating income 9 amounted to €183.2 million in 2010, or 16.6% of sales, up 26.8% year on year, above the 15% growth target set a year ago.
The effective tax rate amounted to 13.5% of result of continued activities before tax excluding the share of loss from associates, compared to an effective tax rate of 6.3% in 2009 when the Group had benefited from a tax relief relating to the favourable settlement of a previous tax dispute. Excluding non-recurring operational, financial and fiscal items, the Group’s effective tax rate amounted to 17.2% in 2010, compared to 11.1% in 2009.
In 2010, the Group recorded a share of loss from associated companies of €(12.8) million representing its share in Inspiration Biopharmaceuticals Inc.’s net loss consolidated since January 2010, and a non-recurring net loss of €5.9 million further to the depreciation of an underlying asset, resulting from an increase in the discount rate of its future cash flows. In 2009, the Group did not record any share of loss from associated companies.
Consolidated net profit amounted to €95.7 million in 2010 (attributable to the shareholders of Ipsen S.A.: €95.3 million), down 39.1% compared to €157.2 million (attributable to the shareholders of Ipsen S.A.: €156.6 million) in 2009. The fully diluted earnings per share amounted to €1.13, down 39.2% from €1.86 in 2009.
The 2010 consolidated net income was strongly and notably impacted by:
- The net impacts of the non-recurring items that affected the Group’s operating income, as described above;
- The non-recurring depreciation of €15.2 million related mainly to the reduction of the book value of some deferred tax assets considering their local statute of limitations and further to new development and commercialisation sales prospects of IGF-I;
- a €5.9 million non recurring net loss from associates related to an increase in the discount rate of Inspiration Biopharmaceuticals Inc. future cash flows.
9 « Recurring adjusted »: Reconciliations between operating results and recurring adjusted operating results as of 31 December 2010 and 2009 are detailed in appendix 4.
Excluding the impacts of the purchase price allocation on the Group’s acquisitions and the non-recurring elements mentioned above, the recurring adjusted 10 fully diluted EPS amounted to €1.64 as of 31 December 2010, up 2.5% compared to €1.60 a year ago.
Net cash generated by operating activities amounted to €253.9 million in 2010, nearly stable year-on-year. At 31 December 2010, the net cash position 11 stood at €156.0 million after its subscription of newly issued shares and bonds of Inspiration Biopharmaceuticals Inc. during the year, compared to €185.6 million a year ago.
Total milestones received in cash by the Group but not yet recognized as revenues in its consolidated income statement amounted to €215.9 million at 31 December 2010, compared to €230.3 million a year earlier.
Dividend for the 2010 financial year proposed for the approval of Ipsen’s shareholders assembly
Ipsen’s Board of Directors, which gathered on 1 March 2011, has decided to propose at Ipsen’s annual shareholders’ meeting to be held on May 27, 2011, the payment of a dividend of €0.80 per share, up 6.7% year-on-year and representing a pay-out ratio of around 71% (attributable to the Group’s shareholders) of consolidated net profit and of around 49%(attributable to the Group’s shareholders) of recurring adjusted consolidated net profit..
Financial objectives for 2011
Ipsen confirms its global biopharmaceutical profile, driven by dynamic Specialty care sales.
Commenting on the Group’s perspectives, Marc de Garidel added: « Ipsen’s development and growth rely on particularly solid fundamentals. Ipsen will thus continue to leverage its talented and motivated teams, its international commercial presence, its innovative and differentiated R&D platforms, and its drug portfolio combining products with high sales potential, products which are well established on their markets and innovative therapeutic solutions in late stage clinical trials. Looking forward, Ipsen is currently conducting a thorough strategic review of its assets to identify the growth drivers that will enable the Group to maximize its full potential.”
As a result and on the basis of currently available information, the Group has set for itself the following objectives for 2011:
- Specialty Care drug sales growth close to 8.0% year-on-year
- Primary Care drug sales decrease of 8.0% to 10.0% year-on-year, notably pending the evolution in France.
The above objectives are set excluding any foreign exchange impacts.
10 « Recurring adjusted »: Reconciliations between operating results and recurring adjusted operating results as of 31 December 2010 and 2009 are detailed in appendix 4
11 Net cash and cash equivalents : Cash and cash equivalents and securities held for sale after deduction of bank overdrafts, short-term bank borrowings, other financial liabilities plus or minus derivative financial instruments.
Press conference (in French)
Ipsen will host a press conference on Wednesday 2 March 2011 at 9:00 a.m. (Paris time, GMT + 1) at its headquarters in Boulogne-Billancourt (France).
Meeting, webcast and Conference Call (in English) for the financial community
Ipsen will host an analyst meeting on Wednesday 2 March 2011 at 2:00 p.m. (Paris time, GMT+1) at its headquarters in Boulogne-Billancourt (France). A web conference (audio and video webcast) and conference call will take place simultaneously. The first one will be available at www.ipsen.com for 3 months. Participants in the conference call should dial in approximately 5 to 10 minutes prior to its start. No reservation is required to participate. The conference ID is 888418. Phone numbers to call in order to connect to the conference are: from France and continental Europe +33 (0)1 70 99 32 08, from UK +44 (0) 207 162 0077 and from the United States +1 334 323 6201. No access code is required. A recording will be available shortly after the call. Phone numbers to access the replay of the conference are: from France and continental Europe +33 (0)1 70 99 35 29, from UK +44 (0) 207 031 4064 and from the United States +1 954 334 0342 and access code is 888418. This replay will be available for one week following the meeting.
About Ipsen
Ipsen is a global biopharmaceutical group, with sales exceeding 1.1 billion euros in 2010. The Group has total worldwide staff of more than 4,400 employees, of which more than 900 contribute to the discovery and development of innovative drugs for patient care. Ipsen’s development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology and on primary care drugs. This strategy is supported by an active policy of partnerships. Ipsen’s research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit our website at www.ipsen.com .
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Notably, future currency fluctuations may negatively impact the profitability of the Group and its ability to reach its objectives. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
APPENDICES
RISK FACTORS
The Group operates in an environment which is undergoing rapid change and exposes its operations to a number of risks, some of which are outside its control. The risks and uncertainties set out below are not exhaustive and the reader is advised to refer to the Group’s 2009 Registration Document available on its website (www.ipsen.com ).
- The Group is dependent on the setting of prices for medicines and is vulnerable to the possible reduction of prices of certain of its products by public or private payers or to their possible withdrawal from the list of reimbursable products by the relevant regulatory authorities in the countries where it does business. In general terms, the Group is faced with uncertainty in relation to the prices set for all its products, in so far as medication prices have come under severe pressure over the last few years as a result of various factors, including the tendency for governments and private payers to reduce prices or reimbursement rates for certain drugs marketed by the Group in the countries in which it operates, or even to remove those drugs from lists of reimbursable drugs. For example, the reimbursement rate of Ginkor Fort® in France was lowered from 35% to 15%. The product was finally withdrawn from the list of reimbursable drugs on 1 January 2008. At the same time, Ipsen sold its Ginkor Fort® marketing licences for France, Monaco and Andorra to the GTF Group with effect from 1 January 2008. Ginkor Fort® generated sales of €9.6 million in France in 2010, while in France in 2007, Ginko Fort® generated €34.1 million. The reimbursement rate for drugs with a low or insufficient therapeutic value (Service Médical Rendu Faible ou Insuffisant) , including Tanakan® was lowered to 15% on 1 April 2010. Additionally, on January 15th 2011, the French Health Minister announced a set of new rules on drugs with an insufficient therapeutic value (Service Médical Rendu Insuffisant) that include Tanakan® : “In the absence of specific notice from the Health Minister, the social security will no longer reimburse this class of drugs”.
- The Group depends on third parties to develop and market some of its products which generates or may generate substantial royalties for the Group, but these third parties could behave in ways which cause damage to the Group’s business. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance.
- Actual results may depart significantly from the objectives set by the management given that a new product can appear to be promising at a development stage or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons.
- The Research and Development process typically lasts between eight and twelve years from the date of a discovery to a product being brought to market. This process involves several stages; at each stage, there is a substantial risk that the Group could fail to achieve its objectives and be forced to abandon its efforts in respect of products in which it has invested significant amounts. Thus, in order to develop viable products from a commercial point of view, the Group must demonstrate, by means of pre-clinical and clinical trials, that the molecules in question are effective and are not harmful to humans. The Group cannot be certain that favourable results obtained during pre-clinical trials will subsequently be confirmed during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safety and efficacy of the product in question such that the required marketing approvals can be obtained.
- The Group must deal with or may have to deal with competition (i) from generic products, particularly in relation to Group products which are not protected by patents, for example, Forlax® or Smecta® (ii), products which, although they are not strictly identical to the Group’s products or which have not demonstrated their bioequivalence, may obtain a marketing authorisation for indications similar to those of the Group’s products pursuant to the bibliographic reference regulatory procedure (well established medicinal use) before the patents protecting its products expire. Such a situation could result to the Group losing market share which could affect its current level of growth in sales or profitability.
- Third parties might claim the benefit of intellectual property rights in respect to the Group’s inventions. The Group provides the third parties with which it collaborates (including universities and other public or private entities) with information and data in various forms relating to the research, development, manufacturing and marketing of its products. Despite the precautions taken by the Group with regard to these entities, in particular of a contractual nature, they (or certain of their members or affiliates) could claim ownership of intellectual property rights arising from the trials carried out by their employees or any other intellectual property right relating to the Group’s products or molecules in development.
- The Group’s strategy includes acquiring companies or assets which may enable or facilitate access to new markets, research projects or geographical regions or enable it to realise synergies with its existing businesses. Should the growth prospects or earnings potential of such assets as well as valuation assumptions change materially from initial assumptions, the Group might be under the obligation to adjust the values of these assets in its balance sheet, thereby negatively impacting its results and financial situation.
- The marketing of certain products by the Group has been and could be affected by supply shortages and other disruptions. Such difficulties may be of both a regulatory nature (the need to correct certain technical problems in order to bring production sites into compliance with applicable regulations) and a technical nature (difficulties in obtaining supplies of satisfactory quality or difficulties in manufacturing active ingredients or drugs complying with their technical specifications on a sufficiently reliable and uniform basis). This situation may result in inventory shortages and/or in a significant reduction in the sales of one or more products.
- In certain countries exposed to significant public deficits, and where it sells its drugs directly to public hospitals, the Group could experience discount or lengthened payment terms or difficulties in recovering its receivables in full. In Greece notably, which represented in 2010 approximately 1.5% of its consolidated sales, and where payment terms from public hospitals are particularly long, the Group is closely monitoring the current situation. More generally, the Group may also be unable to purchase sufficient credit insurance to protect itself adequately against the risk of payment default from certain customers worldwide. Such situations could negatively impact the Group’s activities, financial situation and results.
- In the normal course of business, the Group is or may be involved in legal or administrative proceedings. Financial claims are or may be brought against the Group in connection with some of these proceedings.
MAJOR DEVELOPMENTS
During the fourth quarter of 2010, major developments included:
- On October 11, 2010 – Ipsen announced that it had sold its shares in PregLem Holding SA to Gedeon Richter Plc, as had all PregLem’s other shareholders. In June 2007, the Group spun off to PregLem, then a newly-formed, privately held Swiss biopharmaceutical company, a sulfatase inhibitor and a somatostatin analogue (PGL1001and PGL2001, respectively), patents and know-how for use in the field of human reproductive medicine. In parallel, Ipsen subscribed to newly issued shares of Preglem, representing a c.15 % minority interest in its share capital. PregLem’s lead product, PGL4001 (Esmya™), successfully completed Phase III clinical trials in June 2010 for the treatment of uterine myoma. Ipsen has received initial proceeds of CHF 6 million from the sale of its PregLem shares. Additionally, subject to PGL1001 and PGL2001 being granted marketing approvals, Ipsen will notably receive mid single digit royalties on PregLem’s future net sales of these products. On December 14, 2010 Ipsen was informed that it would receive a further payment of CHF 5.5 million as PGL4001 (Esmya™) US marketing rights were successfully licenced out to a partner;
- On October 11, 2010 – Ipsen’s board of directors announced the departure of Jean-Luc Bélingard and the appointment of Marc de Garidel as Chairman and Chief Executive Officer. Marc de Garidel took over from Jean-Luc Bélingard on November 22, 2010;
- On October 19, 2010 – Ipsen announced that the European Commission had granted orphan drug status for OBI-1 for the treatment of hemophilia. OBI-1 is designed to treat individuals with hemophilia who have developed inhibitory antibodies (inhibitors) against human Factor VIII (hFVIII). The orphan drug status would trigger a 10-year market exclusivity for OBI-1 in the European Union after its marketing approval. The U.S. Food & Drug Administration (FDA) issued an Orphan Drug Designation for OBI-1 in March 2004;
- On November 19, 2010 – Ipsen announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) had initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder. Under the terms of their partnership agreement signed in January 2010, Inspiration in-licensed OBI-1 from Ipsen, and is responsible for the clinical development, regulatory process and commercialization of the product. In the context of this first phase III clinical study initiation, Ipsen has subscribed to a US$50 million (€36.7 million) newly issued convertible note by Inspiration, bringing its fully diluted share ownership position in Inspiration to about 34.0%;
- On December 10, 2010 – the Afssaps announced that it had taken note of the preliminary results of the SAGHE study (“Santé Adulte GH Enfant” or “Adult health GH child”) started in October 2007 that showed an increased risk of higher death rate in adults that have been exposed to high doses (above indication) of GH as children. Since then both the FDA and EMEA have said that no direct correlation between the pediatric use of GH and higher adult death rate could be proved;
- On December 15, 2010 – Ipsen announced that the preliminary data from the ongoing phase IIb study in patients with acromegaly for its chimeric compound BIM 23A760 did not meet the expected inhibition of growth hormone(GH) and IGF-1 levels after repeat dosing. Preliminary phase IIb data showed a strong dopaminergic activity but only weak evidence of somatostatinergic activity. No safety concerns have been observed throughout the trial. Consequently, Ipsen decided to discontinue the development of BIM 23A760.
After the close of the period under review, major developments included:
- On February 2, 2011 - Ipsen announced that Roche informed it on its decision to return taspoglutide to Ipsen. Roche’s decision is based on the analysed data stemming from the root cause analysis carried-out on both nausea and hypersensitivity. According to the agreements signed with Roche in 2003 and 2006, Ipsen is entitled to the full body of data generated by Roche. Ipsen will thouroughly assess the available data to determine potential further partnership opportunities. Given the level of required investment, Ipsen does not intend to clinically develop taspoglutide on its own.
- On February 3, 2011 – Ipsen announced that its partner Inspiration Biopharmaceuticals Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and the prevention of bleeding in individuals with hemophilia B. According to Inspiration, results of the Phase I portion of an ongoing IB1001 clinical study demonstrated non-inferiority of IB1001 in achieving overall levels of replacement facto compared to BeneFIX®, the only approved recombinant FIX product for the treatment of hemophilia B. Currently, IB1001 is in Phase III and safety and efficacy results are expected later this year.
- On February 25, 2011 - Ipsen and bioMérieux announced that they have entered into a partnership to create a global collaboration in theranostics, with a focus on hormone-dependent cancers. The two companies have signed a framework agreement to leverage their expertise and resources to develop a personalized approach to medicine based on Ipsen’s broad portfolio of innovative compounds and bioMérieux’s diagnostic tests. Both companies will jointly identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.
- On March 2, 2011 – GTx announced that a decision has been taken with its European partner Ipsen to terminate their agreement on the development of toremifene citrate for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy.
ADMINISTRATIVE MEASURES
European governments continued introducing various measures targeting the reduction of public health expenses.
In a context of financial and economic crisis 2010 has seen an acceleration in new, and proactive measures, affecting the Group sales and profitability in 2010 and the 6 year-long impact of this will be felt in 2011.
The countries most affected by the crisis such as Romania, the Czech Republic and Greece announced price reductions on the basis of international price references by harmonizing with the lowest European prices.
At the same time, Romania introduced an 8% tax on drug sales. This measure has been enforced since the fourth quarter of 2009. The Czech Republic announced its intention to limit the reimbursement level of various therapeutic classes to the lowest levels of the same therapeutic classes in Europe, which could lead to price reductions in the order of 20% (voted measure, implementation pending).
In Greece, a price reduction by 27% was implemented from May to September and a new (incomplete) price list was published at the beginning of September (with a return to initial prices except for NutropinAq® whose price lowered by 5%). The other prices are still to be published (Decapeptyl® et Dysport® are concerned).
Other Western European countries, although less affected by the crisis, also announced a series of restrictive measures:
- The Netherlands reviewed their reference prices, leading to declines of 20% to 45% on certain products (October 2009).
- Ireland introduced a 4% tax on drug sales (February 2010), and has just announced a belt-tightening measure aiming to save €140 million.
- In addition to the 7.5% tax on drug sales since June 2010, Spain introduced a price reduction by 30% for products which have a generic or a biosimilar product marketed in at least on of the European countries.
- As of 1 August 2010, Germany increased its tax on sales of drugs reimbursed by social security from 6% to 16% (August 2010).
- Italy announced a series of measures aiming to save €600 million (mainly via price reductions on products with generics (the impact on Ipsen is minor).
- Belgium has increased the price reduction percentage applied to old commercialised products from 12 to 15% for products on the market for more than 12 years, and from 15% to 19% for products on the market for more than 15 years.
- On 16 April 2010 in France certain drugs, whose Medical Benefit (SMR) has been evaluated as “weak” or “insufficient to justify reimbursement” by the French National Authority for Health (HAS) (including in particular Tanakan® ) have had their reimbursement rates reduced from 35% to 15%.
Price reductions have also been implemented in particular on Adrovance® whose price was reduced by 25% in May 2010, and on the Sartans theraupeutic class to which Nisis® and Nisisco® belong with a price reduction of 11% from 1 September 2010.
Additionally, on January 15th 2011, the French Health Minister announced a set of new rules on drugs with an insufficient therapeutic value (Service Médical Rendu Insuffisant) that include Tanakan® : “In the absence of specific notice from the Health Minister, the social security will no longer reimburse this class of drugs”.
Comparison of consolidated income statement for 2010 and 2009
| December 31, 2010 | December 31, 2009 | % | ||||||||
| (in million euros) |
%
of sales |
%
of sales |
change | |||||||
| Sales | 1,100.2 | 100.0% | 1,032.8 | 100.0% | 6.5% | |||||
| Other revenues | 70.1 | 6.4% | 79.6 | 7.7% | -11.9% | |||||
| Revenues | 1,170.3 | 106.4% | 1,112.4 | 107.7% | 5.2% | |||||
| Cost of goods sold | (236.2) | -21.5% | (237.8) | -23.0% | -0.7% | |||||
| Research and development expenses | (221.1) | -20.1% | (197.3) | -19.1% | 12.1% | |||||
| Selling expenses | (422.8) | -38.4% | (396.1) | -38.4% | 6.7% | |||||
| General and administrative expenses | (98.3) | -8.9% | (88.5) | -8.6% | 11.1% | |||||
| Other operating income and expenses | 48.2 | 4.4% | (9.7) | -0.9% | - | |||||
| Amortization of intangible assets | (11.1) | -1.0% | (10.5) | -1.0% | 5.7% | |||||
| Restructuring costs | - | - | - | - | - | |||||
| Impairment losses | (100.2) | -9.1% | - | - | - | |||||
| Operating income | 128.8 | 11.7% | 172.5 | 16.7% | -25.3% | |||||
| Recurring Adjusted operating income (1) | 183.2 | 16.6% | 144.4 | 14.0% | 26.8% | |||||
| – Investment income | 2.2 | 0.2% | 2.7 | 0.3% | -17.1% | |||||
| – Costs of financing | (1.6) | -0.1% | (4.4) | -0.4% | -64.0% | |||||
| Net financing Cost | 0.7 | 0.1% | (1.7) | -0.2% | - | |||||
| Other financial income and expense | (4.1) | -0.4% | (3.5) | -0.3% | 17.0% | |||||
| Income taxes | (17.0) | -1.5% | (10.6) | -1.0% | 60.1% | |||||
| Share of profit/loss from associated companies | (12.8) | -1.2% | - | - | ||||||
| Net profit / loss from continuing operations | 95.7 | 8.7% | 156.7 | 15.2% | -38.9% | |||||
| Net profit / loss from discontinued operations | - | - | 0.5 | - | - | |||||
| Consolidated net profit | 95.7 | 8.7% | 157.2 | 15.2% | -39.1% | |||||
| – Attributable to shareholders of Ipsen | 95.3 | - | 156.6 | - | - | |||||
| – Minority interests | 0.4 | - | 0.6 | - | - | |||||
1 The reconciliations between results and recurring adjusted results as of 31 December 2010 and 2009 are detailed in appendix 4.
- Sales
Consolidated Group sales reached €1,100.2 million in 2010, up 6.5% year-on-year or up 5.0% excluding foreign exchange impact.
- Other revenues
Other revenues amounted to €70.1 million in 2010, down 11.9% compared with €79.6 million in 2009.
Other revenues breakdown is as follows:
| (in million euros) | December 31, 2010 | December 31, 2009 | Change | |||||
| In value | in % | |||||||
| Breakdown by type of revenue | ||||||||
| – Royalties received | 6.2 | 41.2 | (35.0) | -85.0% | ||||
|
– Milestone payments – licensing agreements12 |
33.6 | 27.9 | 5.7 | 20.4% | ||||
| – Other (co-promotion revenues, re-billings) | 30.3 | 10.5 | 19.8 | 190.3% | ||||
| Total | 70.1 | 79.6 | (9.5) | -11.9% | ||||
- Royalties received amounted to €6.2 million in 2010, a decrease of €35.0 million over the previous year. The 2009 accounts included a non recurring amount of €39.2 million, following the resolution of a dispute. Adjusting for this non-recurring item in 2009, royalties have increased by €4.1 million year-on-year.
Milestone payments relating to licensing agreements amounted at December 31, 2010 to €33.6 million, an increase of €5.7 million, primarily composed of income from the agreements with Medicis, Galderma and Recordati. In addition, the Group recognized milestones from Menarini on Adenuric® and from Inspiration Biopharmaceuticals Inc. on OBI-1.
- Other revenues amounted to €30.3 million in 2010 compared with €10.5 million a year earlier, mainly impacted by OBI-1 industrial development expenses of €15 million, that the Group invoiced to Inspiration Biopharmaceuticals Inc. .Moreover, the Group, as it did last year, still recorded revenues from its French co-promotion contracts.
- Cost of goods sold
In 2010, cost of goods sold amounted to €236.2 million, representing 21.5% of sales compared to 23.0% the previous year.
The marked improvement in the COGS to sales ratio both reflected an enhanced productivity and a favourable mix associated with the growth in specialty care products sales.
- Research and development expenses
At 31 December 2010, research and development expenses increased by €23.8 million year-on-year, reaching €221.1 million, i.e. 20.1% of sales, as compared to 19.1% for the same period in 2009. Excluding the OBI-1 industrial development expenses which were entirely billed to Inspiration Biopharmaceuticals Inc., research and development expenses represented 18.8% of sales, up 1.8% year-on-year at constant exchange rate.
12 Milestone payments relating to licensing agreements represents primarily recognition of payments received over the life of partnership agreements.
The table below provides a comparison of research and development expenses booked during 2010 and 2009.
| December 31, 2010 | December 31, 2009 | Change | ||||||
| (in million euros) | In value | in % | ||||||
| Breakdown by expense type | ||||||||
| – Drug-related research and development (1) | (192.1) | (166.8) | (25.2) | 15.1% | ||||
| – Industrial development (2) | (23.7) | (25.9) | 2.2 | -8.6% | ||||
| – Strategic development (3) | (5.4) | (4.5) | (0.8) | 18.0% | ||||
| Total | (221.1) | (197.3) | (23.8) | 12.1% | ||||
(1) Drug-related research & development is aimed at identifying new agents, determining their biological characteristics and developing small-scale manufacturing processes. Pharmaceutical development is the process through which active agents become drugs approved by regulatory authorities and is also used to improve existing drugs and to search new therapeutic indications for them. The expenses relating to patents are also included in this type of expense.
(2) Industrial development includes chemical, biotechnical and development-process research costs to industrialise small-scale production of agents developed by the research laboratories.
(3) Strategic development includes costs incurred for research into new product licences and establishing partnership agreements.
- Drug-related research and development expenses increased by 15.1% year on year. The major research and development projects conducted during the period are the clinical development of Somatuline® in neuroendocrine tumours (NET), the Post Marketing Approval studies requested by the FDA on Dysport® , the phase II clinical study for the sulfatase inhibitor Irosustat (BN-83495), and the analysis of the clinical trials results for Tanakan® . Furthermore, during this period, the Group recorded costs relating to the discontinuation of the BIM23A760 research program in acromegaly and those relating to the end of a collaboration agreement with a university.
- Industrial development expenses decreased by 8.6% year-on-year, mainly due to the progressive transfer of some costs related to the botulinum toxin production site into the cost of goods sold. A large amount of the expenses recorded in 2010 were related to the preparation and the production of OBI-1 clinical batches, that was billed to Inspiration Biopharmaceuticals Inc. and recognised in “other revenues”.
- Selling, general and administrative expenses
Selling, general and administrative expenses amounted to €521.1 million in 2010, representing 47.4% of sales, an increase of 7.5% year-on-year.
The table below provides a comparison of selling, general and administrative expenses during 2010 and 2009:
| December 31, 2010 | December 31, 2009 | Change | ||||||
| (in million euros) | In value | in % | ||||||
| Breakdown by expense type | ||||||||
| Royalties paid | (43.7) | (41.7) | (2.0) | 4.7% | ||||
| Other sales and marketing expenses | (379.1) | (354.4) | (24.7) | 7.0% | ||||
| Selling expenses | (422.8) | (396.1) | (26.7) | 6.7% | ||||
| General and administrative expenses | (98.3) | (88.5) | (9.8) | 11.1% | ||||
| Total | (521.1) | (484.6) | (36.5) | 7.5% | ||||
-
Selling expenses
amounted to €422.8 million in 2010 or 38.4% of
sales, up 6.7% year-on-year, compared with €396.1 million, or 38.4% of
sales in 2009.
- Royalties paid to third parties on sales of products marketed by the Group during 2010 amounted to €43.7 million or 4.0% of sales, up 4.7% year-on-year.
- Other selling expenses in 2010 increased by 7.0% year-on-year, amounting to €379.1 million or 34.5% of sales, as compared with €354.4 million, or 34.3% of sales for the same period in 2009. This increase is mainly the result of the sales efforts to support the growth of Somatuline® and Dysport® in North America and the launches of Decapeptyl® 6 month and Adenuric® in France. Furthermore, this increase reflects the Group’s selective allocation policy to growth geographies such as China and Russia, in the context of declining French Primary care sales. Other selling expenses also included some set-up costs related to the establishment of direct commercial platforms in Brazil and Tunisia. Moreover, the Group wrote-down some receivables, mainly from public hospitals, particularly in Southern Europe (Greece, Spain, Portugal and Italy).
- General and administrative expenses in 2010 amounted to €98.3 million or 8.9% of sales, up €9.8 million compared with €88.5 million or 8.6% of sales in 2009. This increase is mainly due to costs relating to the reorganization of some Group support services that occurred at year-end.
- Other operating income and expenses
Other operating income and expenses recorded by the Group in 2010 represented a net income of €48.2 million. Total other operating income amounted to €61.6 million consisting on the one hand of €48.7 million for the accelerated recognition of the deferred revenues following Roche’s decision - announced on 2 February 2011 - to return taspoglutide’s development rights to the Group, and on the other hand of the write-back of a €11.3 million potential liability in connection with Tercica Inc.’ buyout because the Group judged the event unlikely to arise.
Other operating expenses amounted to €13.5 million, mainly including expenses relating to the Group’s headquarters, change of Chairman and CEO and some non-recurring fees.
In 2009, the other operating income and expenses amounted to €(9.7) million, comprising some expenses relating to the integration of the Group’s North American subsidiaries.
- Amortization of intangible assets
In 2010, the amortization of intangible assets amounted to €11.1 million, a slight increase compared with the €10.5 million recorded in the previous year. This item consists mainly of the amortization of the IGF-I licence recognized within the framework of the purchase price allocation related to the Group’s transaction in North America in 2008 and of the beginning of the amortization of Decapeptyl® 6 month licence marketed since February 2010.
- Restructuring costs
The Group recorded no restructuring costs in 2010 nor in 2009.
- Impairment losses
As at 31 December 2010, the Group recorded non-recurrent impairment losses of €100.2 million.
In October 2006, the Group had acquired from Tercica Inc. the development and commercialization rights for Increlex® worldwide, except the United States, Japan, Canada, the Middle East and Taiwan. Consequently to the acquisition of Tercica in October 2008, the Group gained full access to this molecule (IGF-I). In the last 12 months, major changes have affected the pharmaceutical environment, in particular in the United States. These changes accelerated during the last few months of 2010, with the occurrence of difficulties, for some patients, to obtain reimbursement by payers of some of the drugs they had been prescribed. In the view of an increasing rate of reimbursement denials and increasing difficulties in supporting patients securing reimbursement, the Group decided to reduce the development and commercial prospects of IGF-I. The Group thus recorded in its 2010 accounts a non-recurring impairment loss of €71.7 million relating to IGF-I.
Moreover, the Group recorded impairment losses of €28.4 million in connection with its agreement in oncology with GTx Inc., and to recent uncertainties that arose in development timelines in neurology.
The Group did not report any impairment loss in 2009.
- Operating income
Based on above items, the operating profit reported for the 2010 period amounted to €128.8 million or 11.0% of total revenues and 11.7% of sales, down 25.3% compared with 2009, when it represented 15.5% of total revenues and 16.7% of sales.
Excluding non recurring items and impairment losses, the Group’s recurring adjusted operating income 13 as at 31 December 2010 amounted to €183.2 million, or 16.6% of sales, up 26.8% year-on-year, compared to €144.4 million in 2009 or 14.0% of consolidated sales.
- Segment reporting: Operating profit by geographical region
Management information reviewed by the Executive Committee is generated based upon the management organization of the regions in which the Group operates. Because of that, operating segments as defined by IFRS 8 correspond to the grouping of related countries.
The operating segments existing as of December 31, 2010 are as follows:
- “Main Western European countries”, which combines France, Italy, Spain, United Kingdom and Germany;
- “Other European countries”, which combines all of the other countries in Western Europe and those of Eastern Europe;
- “North America”, which includes essentially the United States and Canada;
- “Rest of the world”, which includes the other countries not included in the three preceding segments.
13 “Recurring adjusted“: The reconciliations between results and recurring adjusted results as of 31 December 2010 and 2009 are detailed in appendix 4.
The table below provides an analysis of sales, revenues and operating profit by operating segment for the 2010 and 2009 periods:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
